Cornerstone Select Advisors LLC bought a new stake in shares of Enovix Co. (NASDAQ:ENVX – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 26,080 shares of the company’s stock, valued at approximately $283,000.
Other large investors have also modified their holdings of the company. Barclays PLC increased its holdings in Enovix by 376.9% in the 3rd quarter. Barclays PLC now owns 252,012 shares of the company’s stock worth $2,353,000 after acquiring an additional 199,166 shares in the last quarter. Virtu Financial LLC acquired a new position in Enovix in the 3rd quarter valued at $205,000. Franklin Resources Inc. lifted its holdings in Enovix by 81.4% in the 3rd quarter. Franklin Resources Inc. now owns 79,559 shares of the company’s stock valued at $743,000 after purchasing an additional 35,711 shares in the last quarter. B. Riley Wealth Advisors Inc. acquired a new position in Enovix during the third quarter worth about $117,000. Finally, Lpwm LLC purchased a new position in Enovix in the 4th quarter worth approximately $549,000. Institutional investors and hedge funds own 50.92% of the company’s stock.
Insider Activity at Enovix
In other Enovix news, CEO Rajendra K. Talluri sold 300,000 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $9.35, for a total value of $2,805,000.00. Following the transaction, the chief executive officer now directly owns 2,045,301 shares in the company, valued at $19,123,564.35. This represents a 12.79 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 15.70% of the stock is currently owned by corporate insiders.
Enovix Stock Performance
Enovix (NASDAQ:ENVX – Get Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.01. Enovix had a negative net margin of 963.17% and a negative return on equity of 96.99%. The company had revenue of $9.72 million during the quarter, compared to the consensus estimate of $8.77 million. On average, analysts predict that Enovix Co. will post -1.01 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on ENVX. Craig Hallum dropped their target price on Enovix from $20.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, February 20th. TD Securities lowered their price objective on Enovix from $10.00 to $7.00 and set a “hold” rating for the company in a research report on Thursday, May 1st. Benchmark cut their target price on Enovix from $25.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday, April 15th. Cantor Fitzgerald restated an “overweight” rating and set a $30.00 price target on shares of Enovix in a research report on Thursday, February 20th. Finally, B. Riley cut their price objective on Enovix from $17.00 to $12.00 and set a “buy” rating on the stock in a report on Tuesday, April 29th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Enovix currently has an average rating of “Moderate Buy” and an average target price of $17.27.
Check Out Our Latest Research Report on ENVX
About Enovix
Enovix Corporation designs develops and manufactures silicon-anode lithium-ion batteries. It serves wearables and IoT, smartphone, laptops and tablets, industrial and medical, and electric vehicles industries. The company was founded in 2007 and is headquartered in Fremont, California.
Featured Articles
- Five stocks we like better than Enovix
- Investing in Travel Stocks Benefits
- 3 Mid-Cap Medical Stocks Outperforming the Market
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- The Top-Ranked Insider Buys From April by Market Cap
- Where Do I Find 52-Week Highs and Lows?
- Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
Want to see what other hedge funds are holding ENVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enovix Co. (NASDAQ:ENVX – Free Report).
Receive News & Ratings for Enovix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovix and related companies with MarketBeat.com's FREE daily email newsletter.